Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous
studies; however, a large portion of the genetic risk for this disease remains unexplained. …

Background The amyloid β-protein (Aβ) is believed to be the key mediator of Alzheimer's
disease (AD) pathology. Aβ is most often characterized as an incidental catabolic byproduct …

Adverse intra- and extracellular effects of toxic α-synuclein are believed to be central to the
pathogenesis in Parkinson's disease and other disorders with Lewy body pathology in the …

We expanded GWAS discovery for type 2 diabetes (T2D) by combining data from 898,130
European-descent individuals (9% cases), after imputation to high-density reference panels. …

Parkinson’s disease and other alpha-synucleinopathies are progressive neurodegenerative
diseases characterized by aggregates of misfolded alpha-synuclein spreading throughout …

We assembled an ancestrally diverse collection of genome-wide association studies (GWAS)
of type 2 diabetes (T2D) in 180,834 affected individuals and 1,159,055 controls (48.9% non…

Reminiscent of the human prion diseases, there is considerable clinical and pathological
variability in Alzheimer’s disease, the most common human neurodegenerative condition. As in …

The gradual deterioration of cognitive functions in Alzheimer’s disease is paralleled by a
hierarchical progression of amyloid-beta and tau brain pathology. Recent findings indicate that …

Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple
system atrophy are characterized by the abnormal accumulation and propagation of α‐…

Mutations in the tau gene cause frontotemporal dementia with parkinsonism, presumably by
affecting the balance between tau isoforms (with either three or four microtubule-binding …